Protein kinase inhibitors to treat non-small-cell lung cancer

Author： Minuti Gabriele   D'Incecco Armida   Landi Lorenza   Cappuzzo Federico  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.15, Iss.9, 2014-06, pp. : 1203-1213

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Predictive Biomarkers to Tyrosine Kinase Inhibitors for the Epidermal Growth Factor Receptor in Non-Small-Cell Lung Cancer

By  

Current Drug Targets, Vol. 11, Iss. 7, 2010-07 ,pp. : 851-864

Bentham Science Publishers

Access to resources Recommend Favorite

Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer

By  

Current Drug Targets, Vol. 17, Iss. 6, 2016-05 ,pp. : 739-745

Bentham Science Publishers

Access to resources Recommend Favorite

Mechanisms of Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-Small-Cell Lung Cancer: Clinical and Molecular Considerations

By  

Current Medicinal Chemistry, Vol. 18, Iss. 11, 2011-04 ,pp. : 1613-1628

Bentham Science Publishers

Access to resources Recommend Favorite

Spotlight on Gefitinib in Non-Small-Cell Lung Cancer

By Frampton James E.   Easthope Stephanie E.  

American Journal of PharmacoGenomics, Vol. 5, Iss. 2, 2005-01 ,pp. : 133-136

Adis International

Access to resources Recommend Favorite

Vandetanib for the treatment of non-small-cell lung cancer

By Wong Hui-li   de Boer Richard H  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 14, 2011-10 ,pp. : 2271-2278

Informa Healthcare

Access to resources Recommend Favorite